Displaying 25 - 36 of 39
Immune-Mediated and Cholestatic Diseases
5

GSK: Holistic patient care in PBC: moving beyond ALP to QoL - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
5

GSK: Holistic patient care in PBC: moving beyond ALP to QoL - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
5

GSK: Holistic patient care in PBC: moving beyond ALP to QoL - ILC 2022

View
Metabolism, Alcohol & Toxicity
5

IMP: Shining a spotlight on obesity treatment in NAFLD/NASH - ILC 2021

View
Metabolism, Alcohol & Toxicity
5

IMP: Shining a spotlight on obesity treatment in NAFLD/NASH - ILC 2021

View
Metabolism, Alcohol & Toxicity
5

IMP: Shining a spotlight on obesity treatment in NAFLD/NASH - ILC 2021

View
Metabolism, Alcohol & Toxicity
5

IMP: Shining a spotlight on obesity treatment in NAFLD/NASH - ILC 2021

View
Metabolism, Alcohol & Toxicity
5

IMP: Shining a spotlight on obesity treatment in NAFLD/NASH - ILC 2021

View
Viral Hepatitis
2

GSK: HBsAg clearance in chronic hepatitis B: How close is it? - ILC 2021

View
Viral Hepatitis
2

GSK: HBsAg clearance in chronic hepatitis B: How close is it? - ILC 2021

View
Metabolism, Alcohol & Toxicity
5

International Medical Press: Obesity management in NAFLD/NASH: can we do more? - Digital ILC 2020

View
Metabolism, Alcohol & Toxicity
5

International Medical Press: Obesity management in NAFLD/NASH: can we do more? - Digital ILC 2020

View